18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy.

18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy.

UNLABELLED: The aim of this study was to characterize the biologic response of locally advanced breast cancer (LABC) to chemotherapy using (15)O-water-derived blood flow measurements and (18)F-FDG-derived glucose metabolism rate parameters. METHODS: Thirty-five LABC patients underwent PET with (15)O...

Bibliografske podrobnosti
Main Authors:	Tseng, J, Dunnwald, L, Schubert, E, Link, J, Minoshima, S, Muzi, M, Mankoff, D
Format:	Journal article
Jezik:	English
Izdano:	2004

Podobne knjige/članki

Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.
od: Mankoff, D, et al.
Izdano: (2003)

Assessment of Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Using MRI and 18F FDG PET/CT
od: Reem Yusuf AlBuainain, et al.
Izdano: (2025-01-01)

Role of F-18 FDG PET/CT in Predicting Response to Neoadjuvant Chemotherapy in Invasive Ductal Breast Cancer
od: Tarik Sengoz, et al.
Izdano: (2023-04-01)

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
od: Alexander M Th Schmitz, et al.
Izdano: (2017-01-01)

Correlation Between 18F-FDG PET/CT SUVmax and Clinicopathological Features, Neoadjuvant Chemotherapy Response in Invasive Ductal Breast Carcinoma Patients
od: LU Shengnan, et al.
Izdano: (2019-02-01)

18F-FDG PET/CT Metrics Are Correlated to the Pathological Response in Esophageal Cancer Patients Treated With Induction Chemotherapy Followed by Neoadjuvant Chemo-Radiotherapy
od: Nicola Simoni, et al.
Izdano: (2020-11-01)

Efficacy of US, MRI, and F-18 FDG-PET/CT for Detecting Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Breast Cancer Patients
od: Umit Turan, et al.
Izdano: (2021-12-01)

Metabolic Radiomics for Pretreatment 18F-FDG PET/CT to Characterize Locally Advanced Breast Cancer: Histopathologic Characteristics, Response to Neoadjuvant Chemotherapy, and Prognosis
od: Seunggyun Ha, et al.
Izdano: (2017-05-01)

Predicting pathological response of locally advanced breast cancer to neoadjuvant chemotherapy: comparing the performance of whole body 18F-FDG PETCT versus DCE-MRI of the breast
od: Alaa Sobhi, et al.
Izdano: (2022-03-01)

The Role of Pretreatment 18F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
od: Yao J, et al.
Izdano: (2021-10-01)

18F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data
od: Florent L. Besson, et al.
Izdano: (2020-07-01)

Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials
od: Mark Muzi, et al.
Izdano: (2024-03-01)

Early response monitoring of neoadjuvant chemotherapy using [18F]FDG PET can predict the clinical outcome of extremity osteosarcoma
od: Inki Lee, et al.
Izdano: (2020-01-01)

The role of 18F-FDG PET/MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis
od: Milad Ghanikolahloo, et al.
Izdano: (2024-11-01)

Prediction of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer by using a deep learning model with 18F-FDG PET/CT.
od: Gülcan Bulut, et al.
Izdano: (2023-01-01)

Prediction of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer by using a deep learning model with 18F-FDG PET/CT
od: Gülcan Bulut, et al.
Izdano: (2023-01-01)

Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis
od: Sangwon Han, et al.
Izdano: (2020-10-01)

18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study
od: Perrin E. Romine, et al.
Izdano: (2021-08-01)

Correlation between 18F-FDG Positron-Emission Tomography 18F-FDG Uptake Levels at Diagnosis and Histopathologic and Immunohistochemical Factors in Patients with Breast Cancer
od: Gamze Uğurluer, et al.
Izdano: (2016-07-01)

[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.
od: Isabella Raccagni, et al.
Izdano: (2018-01-01)

Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
od: In Hee Lee, et al.
Izdano: (2020-11-01)

Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Using Convolutional Neural Network of Tumor Center <sup>18</sup>F-FDG PET Images
od: Jingyu Kim, et al.
Izdano: (2021-10-01)

[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial
od: Giulia Polverari, et al.
Izdano: (2020-10-01)

The kinetics of 18F-FDG in lung cancer: compartmental models and voxel analysis
od: Erica Silvestri, et al.
Izdano: (2018-08-01)

Does baseline [18F] FDG-PET/CT correlate with tumor staging, response after neoadjuvant chemoradiotherapy, and prognosis in patients with rectal cancer?
od: Letizia Deantonio, et al.
Izdano: (2018-10-01)

Incidental F18-FDG Breast Uptake: How to Consider and Manage
od: Francesco Bertagna, et al.
Izdano: (2014-05-01)

18F-FDG PET/CT-based deep learning radiomics predicts 5-years disease-free survival after failure to achieve pathologic complete response to neoadjuvant chemotherapy in breast cancer
od: Xingxing Zheng, et al.
Izdano: (2023-12-01)

Value of 18F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype
od: Cornelis M. de Mooij, et al.
Izdano: (2021-11-01)

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
od: Han Wonshik, et al.
Izdano: (2011-10-01)

Breast Cancer: Neoadjuvant Chemotherapy
od: Barbara F. Shea, et al.
Izdano: (2007-03-01)

Breast Cancer: Neoadjuvant Chemotherapy
od: Barbara F. Shea, et al.
Izdano: (2015-05-01)

Breast Cancer: Neoadjuvant Chemotherapy
od: Barbara F. Shea, et al.
Izdano: (2007-03-01)

Breast Cancer: Neoadjuvant Chemotherapy
od: Barbara F. Shea, et al.
Izdano: (2015-05-01)

Breast Cancer: Neoadjuvant Chemotherapy
od: Barbara F. Shea, et al.
Izdano: (2015-05-01)

Breast Cancer: Neoadjuvant Chemotherapy
od: Barbara F. Shea, et al.
Izdano: (2007-03-01)

The value of 18F-FDG PET/CT imaging in breast cancer staging
od: Ulkem Yararbas, et al.
Izdano: (2018-02-01)

Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals
od: Ioannis Iakovou, et al.
Izdano: (2018-10-01)

Performance of 18F-FDG PET/MRI and its parameters in staging and neoadjuvant therapy response evaluation in bladder cancer
od: Tianhang Li, et al.
Izdano: (2024-05-01)

18F‐FDG PET/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma
od: Shuohua Wang, et al.
Izdano: (2023-08-01)

The value of 18F-fluorodeoxyglucose PET (18F-FDG PET) and MRI spectroscopy in underpinning suspicious breast cancer
od: Shaharuddin, Shazreen, et al.
Izdano: (2018)